Thus, we used ultra-low dose IL-2 (approximately 7-fold lower than low dose) treatment in the multiple low dose streptozotocin (STZ) mouse model of T1D and assessed its effectiveness in preventing the disease. The gene discussed is IL2; the disease is type 1 diabetes mellitus.